Seelos therapeutics raises $20 million in private placement of senior secured convertible note

New york, nov. 24, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "note") and shares of seelos common stock (the "closing shares") to lind global asset management v, llc, managed by the lind partners, a new york institutional fund manager and an existing investor in seelos. seelos will receive $20.0 million in gross proceeds.
SEEL Ratings Summary
SEEL Quant Ranking